Open AccessIncorporating Fecal Calprotectin Into Clinical Practice for Patients With Moderate-to-Severely Active Ulcerative Colitis Treated With Biologics or Small-Molecule Inhibitors
Author(s) -
Parambir S. Dulai,
Robert Battat,
Maria Barsky,
Nghia Nguyen,
Christopher Ma,
Neeraj Narula,
Mahmoud Mosli,
Niels Vande Casteele,
Brigid S. Boland,
Larry J. Prokop,
M. Hassan Murad,
Geert R. D’Haens,
Brian G. Feagan,
William J. Sandborn,
Vipul Jairath,
Siddharth Singh
Publication year - 2020
Publication title -
the american journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.907
H-Index - 252
eISSN - 1572-0241
pISSN - 0002-9270
DOI - 10.14309/ajg.0000000000000596
Subject(s) - medicine , tofacitinib , calprotectin , golimumab , ulcerative colitis , infliximab , gastroenterology , endoscopy , faecal calprotectin , vedolizumab , proctitis , inflammatory bowel disease , disease , rheumatoid arthritis
We applied the Grading of Recommendations, Assessment, Development, and Evaluation framework to evaluate the performance of fecal calprotectin (FC) as an alternative to endoscopy in patients with moderate-to-severe ulcerative colitis (UC) treated with a biologic agent or tofacitinib.